Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：1
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN
    Martinez-Janez, N.
    Ezquerra, M. Bellet
    Sanchez, L. M. Manso
    Carrasco, F. Henao
    Torres, A. Anton
    Morales, S.
    Ortega, P. Tolosa
    Gil, V. L. Obadia
    Sampedro, T.
    Conejero, R. Andres
    Calvo-Martinez, L.
    Galve-Calvo, E.
    Lopez, R.
    de la Pena, F. Ayala
    Lopez-Tarruella, S.
    de Araguiz, B. A. Hernando Fernandez
    Ruiz, L. Boronat
    Cardenas, T. Martos
    Chacon, J. I.
    Anton, F. Moreno
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (01) : 57 - 65
  • [22] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [23] Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials
    Toi, Masakazu
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Sohn, Joohyuk
    Hae Park, In
    Im, Seock-Ah
    Chen, Shin-Cheh
    Enatsu, Sotaro
    Turner, P. Kellie
    Andre, Valerie A. M.
    Hardebeck, Molly C.
    Sakaguchi, Sachi
    Goetz, Matthew P.
    Sledge, George W., Jr.
    CANCER SCIENCE, 2021, 112 (06) : 2381 - 2392
  • [24] Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2-advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials
    Yang, Lin
    Xue, Jingyi
    Yang, Zhengyu
    Wang, Meixue
    Yang, Ping
    Dong, Yanming
    He, Xianli
    Bao, Guoqiang
    Peng, Shujia
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5590 - +
  • [25] HR+, HER2-Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
    Sammons, Sarah L.
    Topping, Donna L.
    Blackwell, Kimberly L.
    CURRENT CANCER DRUG TARGETS, 2017, 17 (07) : 637 - 649
  • [26] Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2- advanced breast cancer in real-world clinical practice
    Zhong, Bingqian
    Zhang, Jie
    Wu, Jing
    Sun, Langshuang
    Li, Shuhong
    Zeng, Xiaohua
    Gan, Lu
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [27] Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2-advanced breast cancer
    Hao, Chunfang
    Bai, Xuedong
    Zhang, Jie
    Meng, Wenjing
    Tong, Zhongsheng
    THORACIC CANCER, 2023, 14 (01) : 68 - 72
  • [28] Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2-Advanced Breast Cancer?
    Malorni, Luca
    Biganzoli, Laura
    BREAST CARE, 2017, 12 (05) : 288 - 289
  • [29] CDK4/6 inhibitors in HR+/HER2-advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
    Harbeck, Nadia
    Bartlett, Meaghan
    Spurden, Dean
    Hooper, Becky
    Zhan, Lin
    Rosta, Emily
    Cameron, Chris
    Mitra, Debanjali
    Zhou, Anna
    FUTURE ONCOLOGY, 2021, 17 (16) : 2107 - 2122
  • [30] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
12345